• Specialties
    • Cardiology
    • Diabetes
    • Haematology
    • Hepatology
    • Nephrology
    • Neurology
    • Oncology
    • Rheumatology
    • Urology
  • News & Perspective
  • Conference Update
  • Study Update
  • Expert Insight
  • Case Review
  • Meeting Highlight
  • e-CONNECT
  • Login / Sign up
  • Specialties
  • News & Perspective
  • Conference Update
  • Study Update
  • Expert Insight
  • Case Review
  • Meeting Highlight
  • e-CONNECT
  • Cardiology
  • Diabetes
  • Haematology
  • Hepatology
  • Nephrology
  • Neurology
  • Oncology
  • Rheumatology
  • Urology
News & Perspective

Stringent glucose targets may not be beneficial to all diabetic patients

31 Mar,2018

The J-shaped curvilinear association between hemoglobin A1c (HbA1c) and the risk of cardiovascular disease (CVD) remains a controversial concept, considering the lack of consensus regarding the lower threshold of HbA1c.1 To elucidate this issue, Mr. Eric Wan, Dr. Esther Yu, and their team from the U...

Diabetes remission is possible with intensive weight management alone

31 Mar,2018

Type 2 diabetes is generally perceived as progressive and incurable. A new study led by Prof. Roy Taylor of the Newcastle University, UK, now indicated that it is possible to reverse the disease just by losing weight. Almost half of participants who followed a three-phased weight management program ...

Feasibility study of oral insulin brings high hopes in type 2 diabetes

26 Sep,2017

There is still no oral formulation of insulin available clinically, particularly due to the low bioavailability of intact insulin via oral route delivery.1 However, encouraging findings were presented in the President’s Oral Session at the American Diabetes Association's 77th Scientific Sessions. ...

View all
Conference Update

SGLT2-inhibitors in type 1 diabetes: DKA risk can be different between agents

14 Dec,2017

Current therapeutic options for treating type 1 diabetes (T1DM) remain very limited, with insulin being the mainstay of therapy. However, the data presented at the European Association for the Study of Diabetes (EASD) 2017 Annual Meeting have revealed that selective sodium-glucose co-transporter 2 (...

Sustain-6: Semaglutide shows non-inferiority of cardiovascular outcomes to standard care in type 2 diabetes

10 Feb,2017

Semaglutide, a glucagon-like peptide (GLP)-1 agonist developed by Novo Nordisk, has demonstrated non-inferiority in cardiovascular (CV) risk, in fact, a 26% reduced composite risk of CV death, non-fatal myocardial infarction and non-fatal stroke, as compared to placebo in a cohort of >3,000 patie...

EMPA-REG: Empagliflozin delays renal disease progression in T2D

27 Jun,2016

EMPA-REG OUTCOME trial was the first positive FDA-mandated cardiovascular (CV) outcome study for anti-hyperglycemia medicine reported last fall.1 Yet, concerns remain as per whether empagliflozin, as one of the sodium-glucose transporter 2 inhibitors (SGLT2i) that primarily exert glucose-lowering ef...

View all
Popular Post

Stringent glucose targets may not be beneficial to all diabetic patients

31 Mar,2018

The J-shaped curvilinear association between hemoglobin A1c (HbA1c) and the risk of cardiovascular disease (CVD) remains a controversial concept, considering the lack of consensus regarding the lower threshold of HbA1c.1 To elucidate this issue, Mr. Eric Wan, Dr. Esther Yu, and their team from the U...

Diabetes remission is possible with intensive weight management alone

31 Mar,2018

Type 2 diabetes is generally perceived as progressive and incurable. A new study led by Prof. Roy Taylor of the Newcastle University, UK, now indicated that it is possible to reverse the disease just by losing weight. Almost half of participants who followed a three-phased weight management program ...

Interview with the Expert:
Prof. Rury Holman – Insights from the EXSCEL Trial

18 Jan,2018

...

View all
  • About Omnihealth Practice
  • Terms and conditions of use
  • Privacy policy

Omnihealth Practice

Omnihealth Practice appreciates your comments and queries. Please use the form below to send us your message, we will response to you as soon as we can.

Copyright © 2018 by Omnihealth Practice. All Rights Reserved.